Imara announces FDA fast track designation for IMR-687 for the treatment of sickle cell disease

Imara

29 May 2019 - Imara today announced that the U.S. FDA has granted fast track designation to IMR-687, the company’s lead product candidate for the treatment of sickle cell disease. 

IMR-687 is currently being evaluated in a multi-national Phase 2a clinical trial in adult patients.

Read Imara press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track